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Abstract
This narrative review evaluates translational research with respect to ﬁve important risk factors for chronic kidney disease
(CKD): physical inactivity, high salt intake, smoking, diabetes and hypertension. We discuss the translational research around
prevention of CKD and its complications both at the level of the general population, and at the level of those at high risk, i.e.
people at increased risk for CKD or CKD complications. At the population level, all three lifestyle risk factors (physical inactivity,
high salt intake and smoking) have been translated into implemented measures and clear population health improvements
have been observed. At the ‘high-risk’ level, the lifestyle studies reviewed have tended to focus on the individual impact of
speciﬁc interventions, and their wider implementation and impact on CKD practice are more difﬁcult to establish. The
treatment of both diabetes and hypertension appears to have improved, however the impact on CKD and CKD complications
was not always clear. Future studies need to investigate themost effective translational interventions in lowandmiddle income
countries.
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Introduction
Chronic kidney disease (CKD) is increasingly recognized as a glo-
bal public health problem. Peoplewith CKD are at risk of develop-
ing end-stage renal disease (ESRD) and have a notably increased
risk of cardiovascular disease (CVD) and mortality [1–4]. From
1990 to 2010 the age-adjusted death rates attributable to CKD
have increased by 15% [5] and CKD is now the 19th leading
cause of life years lost [3]. While some of this increase may be at-
tributable to increased identiﬁcation and coding, other factors
such as demographic transition to older population proﬁles and
rural to urban population shift in low and middle income coun-
tries must be considered [6].
Worldwide an estimated 8–16% of the general population has
CKD [7]. The prevalence of CKD increaseswith age to about 30% in
people aged over 70 years [8, 9]. Added to this is an anticipated in-
crease in CKD prevalence as a result of the ongoing epidemics
of diabetes, hypertension and obesity [8], all of which (both
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individually and in combination) are important risk factors for
CKD [2]. In addition to the implications for morbidity andmortal-
ity, the growing prevalence of CKD has signiﬁcant implications
for health and social care systems, particularly considering the
high cost of renal replacement therapy, the greatest burden of
which may in future be felt in developing countries [3].
Although dependent to some extent on the causal patho-
physiology, in principle, the development of CKD and its compli-
cations can be (partly) prevented or delayed [7]. In 2013 theWorld
Health Organization’s (WHO) Global Action Plan for the Preven-
tion and Control of Non-communicable Diseases (NCDs) 2013–
2020 was adopted [10]. In this plan, the WHO lists nine public
health targets which will help to reduce the global burden of
NCDs by targeting both lifestyle factors and speciﬁc NCDs
(Figure 1) [10]. Although CKD is not a direct target in this WHO
action plan, the plan does acknowledge the link between major
NCDs, such as diabetes and hypertension, and CKD. Moreover,
ﬁve of the WHO targets are aimed at important CKD risk factors
namely: physical inactivity [11], high dietary salt intake [12],
smoking [13], diabetes and hypertension [2]. In this narrative
review, we will review how the available evidence on these
important CKD risk factors is being translated into the imple-
mentation of measures to prevent CKD and its complications
and to improve public health.
Ideally, translational research aimed at the prevention of CKD
and its complications needs to translate ﬁndings both at the level
of the general population and at the level of those at high risk [14].
In the latter we will consider both people who are at increased
risk of developing CKD (e.g. people with diabetes) and people
with CKD who are at risk of developing complications of CKD.
Focusing on these levels, this narrative review will describe
translational research with respect to the ﬁve risk factors for
CKD mentioned above: physical inactivity [11], high salt intake
[12], smoking [13], diabetes and hypertension [2]. Thus we will
consider both primary and secondary prevention strategies for
CKD in a translational research framework.
Public health translational research framework
There is no clear consensus regarding the term translational
research [15]. Traditionally it concerns the translation from
‘bench-to-bedside’, i.e. using basic science results to develop
Fig. 1. The nine global voluntary targets from the WHO Global Action Plan for the Prevention and Control of NCDs 2013–2020. Reprinted from Global action plan for the
prevention and control of noncommunicable diseases 2013–2020, World Health Organization, Voluntary Global Targets, page 5, Copyright (2013).



























new treatments or diagnostics for patients [15]. In public health
terms translational research is commonly interpreted as the
translation of ‘research into practice’, i.e. ensuring that new re-
search knowledge will reach the intended patients and popula-
tions and that it is implemented correctly with the prospect of
improving health [15].
Both these traditional basic science and public health per-
spectives on translational research have been incorporated into
various linear frameworks [16–18], such as the framework de-
scribed by Khoury et al. [16], which distinguishes ﬁve phases of
translational research (see Box 1):
An alternative nonlinear framework has been proposed by
Ogilvie et al. [19]. This framework was developed speciﬁcally for
the translation of public health research [19]. They argue that
translating research into improvement of public health involves
amuch wider scope than the translation of research by research-
ers alone, as the practice to be inﬂuenced is not limited to clinical
practice or public health practice [19]. We have chosen to use an
adaptation of this framework byOgilvie et al. as the outline for our
review, because this framework reﬂects the complex interactions
involved in translating health research into public health
improvement (Figure 2).
In recent years, translational research has received increased
attention from funding bodies such as the National Institute for
Health Research (NIHR) in the UK [18]. However, there is evidence
that the majority of funding for translational research has still
historically been assigned to the translation from bench-to-
bedside [20] rather than on implementation [21] or population
health impact. As a consequence of this emphasis, most transla-
tional research focuses on this bench-to-bedside translation [15].
Nevertheless one may argue that the translation from ‘research
to practice’, e.g. implementation into health practice, has the po-
tential to beneﬁt more people. It is important to remember that
the greatest beneﬁt to population health may not be achieved
by simply targeting those at highest risk. To cite Rose ‘A large
number of people at a small risk may give rise to more cases of
disease than the small number who are at high risk’ [22]. We
will therefore consider population-level measures and their im-




Many observational studies have shown that in healthy subjects
regular physical activity is associated with reduced morbidity and
all-cause and cardiovascularmortality, leading to the development
of general population physical activity guidelines in many coun-
tries [11, 23, 24]. Increasing physical activity at population level is
a complex topic encompassingmany different strategies including
policies, advocacy, environmental/infrastructure changes, and
awareness and education [23]. These strategies ﬁt in the ‘Public
realm’ box of the Ogilvie model (Figure 2). Several governments
have implemented campaigns to increase physical activity of
their population, such as the ‘exercise 30 min a day’ and ‘10 000
stepsaday’ campaigns in theNetherlandsandBelgium, respective-
ly (http://www.10000stappen.be/; http://www.30minutenbewegen.
nl/home-ik-wil-bewegen.html). In line with this, the WHO Global
Action Plan for the Prevention andControl of Non-communicable
Diseases aims for a ‘10% relative reduction in the prevalence of
physical inactivity’ [10].
There is a wide variety of methods used to increase physical
activity levels of the population, from changing infrastructure
of urban areas to methods of inﬂuencing behavioural change. It
falls outside the scope of this review to describe all of these in de-
tail; however, they are of great relevance for both the general
population and for people at the high-risk level. One speciﬁc ex-
ample is the recent development of the increasing availability
and use ofmobile health applications (‘apps’) and other electron-
ic devices to monitor and adjust physical activity and other
health-related behaviour. This has prompted the US Food and
Drug Administration (FDA) to publish guidance onmobilemedic-
al apps for the industry in 2013 [25]. This guidance clariﬁeswhich
apps are considered to be subject to the FDA authority and the
regulatory requirements that will apply to such apps. A report
by Research2guidance predicted that by 2015, 500 million people
will be using mobile healthcare applications [26]. The develop-
ment and use of apps to monitor physical activity may likely
inﬂuence public health awareness and perhaps modify health-
related behaviour of both the general population and patients.
Yet the effectiveness of these apps in increasing physical activity
needs further study.
Population-level impact
In 2002, 31% of the adult European population reported regularly
undertaking sufﬁcient physical activity, i.e. 30 min of moderate
physical activity≥5 times aweek [27]. Several European countries
have published physical activity trend data, which ﬁts into the
box ‘Health-related behaviour’ of the Ogilvie model (Figure 2).
In the Netherlands, the percentage of the population fulﬁlling
the minimum physical activity level criteria has increased from
52 to 62% in the period from 2001 to 2011 [28]. In the UK, from
1997 to 2012, the percentage of men and women meeting the
physical activity criteria increased from 32 to 43% and 21 to
32%, respectively [29]. Despite the increased physical activity
seen in both the Netherlands [30] and the UK [31], obesity preva-
lence is still increasing in both countries. In the UK the obesity
prevalence increased between 1993 and 2012 from 13.2 to 24.4%
and 16.4 to 25.1% in males and females, respectively [31]. These
data suggest that interventions to increase physical activity are
effective in increasing the physical activity level, but not in de-
creasing the obesity prevalence in the general population [32].
However, increased physical activity is related to various other
health beneﬁts such as improved glycaemic control, reduced
blood pressure and reduced cardiovascular risk [33].
In terms of interventions, a recent systematic review by Laine
et al. [34] concluded that community rail trails, pedometers and
school health education programmes were the most cost-effective
measures to increase physical activity on apopulation level. Prior to
this, Roux et al. [35] had modelled the cost-effectiveness of seven
community-based physical activity interventions, such as commu-
nity-wide campaigns and the creation of physical activity informa-
tion and opportunities, and concluded that all seven strategies
considered were cost effective at reducing the incidence of chronic
Box 1. Translational research framework as described
by Khoury et al. [15]
Phase 0: description and discovery
Phase 1: from discovery to health applications
Phase 2: from health application to evidence guidelines
Phase 3: from guidelines to health practice
Phase 4: from health practice to population health
outcomes



























diseases such as coronary heart disease, ischaemic stroke and type
2 diabetes.
Additional high-risk level measures
Although multiple studies report beneﬁcial impact of physical
activity in people with CKD [36, 37], evidence-based guidelines
with speciﬁc exercise recommendations for people with CKD
are lacking [38, 39]. Nonetheless, multiple guidelines include an
exercise recommendation for people with CKD based on low-
grade evidence [1, 40, 41], which ﬁt into the box ‘Professional
practice’ of the Ogilvie model (Figure 2). For example, Kidney
Disease: Improving Global Outcomes (KDIGO) recommends
encouraging people with CKD to undertake physical activity
compatible with cardiovascular health and tolerance ﬁve times
a week for at least 30 min [1]. Few studies examined exercise ad-
herence by peoplewith CKD [39]. In a randomized controlled trial
inwhich peoplewithCKD received 8weeks of supervised training
followed by 10months of home-based training, self-reported ad-
herence dropped from 70% during the supervised training to 53%
at the end of the 10 months home-based training period [42].
High-risk level impact
In people with CKD exercise training is associated with reduced
body mass index (BMI) and improved physical functioning [42],
such studies ﬁt into the box ‘Intervention studies’ (Figure 2).
Importantly, many people with CKD are older and promoting
physical activity in older subjects is inﬂuenced by speciﬁc
challenges. As expected, individuals aged 65 years or older
often report perceived poor health and symptoms of physical
disabilities as major barriers to physical activity [43]. Despite
these additional barriers for elderly patients, a review by Brawley
et al. [43] has shown that physical activity interventions may still
increase the amount of physical activity in older patients. In
patients with established CVD, randomized trials have shown
that regular physical activity is effective in reducing CVD inci-
dents and in improving life expectancy [11]. In conclusion,
there is good evidence that increasing physical activity is effect-
ive in the secondary prevention of CVD in general, including
some evidence speciﬁcally in CKD.
High dietary salt intake
Population-level measures
The WHO Global Action Plan has set the target of ‘a 30% relative
reduction in mean population salt intake’ [10]. The recom-
mended absolute salt intake by the WHO in 2012 is a dietary in-
take of <5 g/day [44]. It is worth noting that recommended targets
vary across individual European countries, from speciﬁc recom-
mendations such as <9 g/day in the Netherlands to more general
advice such as ‘to avoid salt and food rich in salt’ in Greece and
Hungary [45].
Since an estimated 70%of dietary salt intake inWestern coun-
tries is obtained through bread and processed foods [46], only salt
restriction in bread and processed foods will substantially reduce
dietary salt intake and (possibly) achieve improvement in public
health outcomes. This restriction needs to be implemented by
policy makers or the food industry. In 2014, Webster et al. [47]
identiﬁed 83 countries with national initiatives to reduce dietary
salt intake. Fifty-nine countries, of which 32 European countries,
reported collaboration with the food industry to reduce salt con-
tent of food [47]. These initiatives include both voluntary salt re-
duction targets, which are non-binding agreementswith the food
industry, and mandatory salt reduction targets, which are agree-
ments enforced by legislation or penalty for non-compliance.
Overall, the majority of identiﬁed initiatives related to voluntary
targets implemented parallel to programmes directed at chan-
ging consumer attitudes and behaviour relating to salt [47]. All
Fig. 2. Ogilvie’s translational research framework in the context of chronic kidney disease (adapted from a model by Ogilvie et al. [19]). RRT, renal replacement therapy.



























of these recommendations ﬁt into the ‘Public realm’ box of the
Ogilvie model (Figure 2).
Population-level impact
In an overview of national initiatives to encourage the food indus-
try to reduce salt, Webster et al. [47] identiﬁed 17 countries that
reported a reduction of salt levels in one or multiple products,
nineofwhichwere inEurope.All nineEuropean countries reduced
the salt content of bread, ranging from a 6% reduction in Belgium
to 29% reduction in Ireland [47]. Finland started salt reduction
efforts as early as 1978 including mandatory warning labels for
food products high in salt [48]. By 2002 the Finnish average salt
intake had reduced from 12 to 9 g per day [48]. These studies on
salt intake ﬁt within the box ‘Health-related behaviour’ (Figure 2).
Bibbins-Domingo et al. [49] projected that even minor reduc-
tions in dietary salt intake (e.g. 1 g a day) through population-
wide salt reduction strategies would be cost-effective to reduce
cardiovascular events and lower medical costs. From 1970 to
1995 the cardiovascular mortality decreased by 65% [50] in
Finland. According to Vartiainen et al. [51] 32 and 38% of the
strokemortality reductionwas explained bya decrease in diastol-
ic blood pressure for males and females, respectively. The reduc-
tion in mortality from ischaemic heart disease could be
explained by a decrease in diastolic blood pressure in 15 and
31% of the males and females, respectively [52]. Within the gen-
eral population, dietary salt reduction reduces the risk of cardio-
vascular events and possibly all-cause mortality [53].
Additional high-risk level measures
Although evidence-based clinical practice guidelines for people
with CKD generally recommend reduction in dietary salt intake
[54], the various guidelines report different salt targets. KDIGO re-
commends a salt intake of <2 g/day [55] and the Canadian Society
of Nephrology recommends sodium targets depending on hyper-
tensive status [40]. These guidelines can be considered to be in
the ‘Professional practice’ box of the Ogilvie model (Figure 2).
Restricting dietary salt intake can be challenging and, in clinical
practice, recommended salt targets are often not achieved in peo-
ple with CKD [56, 57]. This may be inﬂuenced by insufﬁcient em-
phasis on salt reduction by care providers [12], yet is likely also
inﬂuenced by patient non-adherence [57]. Dietary salt recom-
mendations can be confusing for patients and the general popu-
lation alike, and adhering to recommended targets is difﬁcult for
individuals. Therefore interventions at the population level, such
as legislation inﬂuencing food manufacturers to reduce salt con-
tent, are themost likely to succeed in reducing dietary salt intake
of both the general population and people with CKD.
High-risk level impact
In people with CKD, salt reduction is a low risk and cost-effective
strategy to reduce blood pressure as compared with blood
pressure-reducing drugs [54]. Salt restriction reduces both hyper-
tension and proteinuria in people with CKD [54, 58]. However a
recent post hoc analysis of the ONTARGET and TRANSCEND trial
found no association between low sodium diet and risk of ESRD
[59]. Unfortunately there are no studies on the effect of salt
reduction on mortality [54].
Smoking
Population-level measures
Smoking is associated with an increased risk of CKD in the gen-
eral population [60]. The WHO target is ‘a 30% relative reduction
in prevalence of current tobacco use in person aged 15+ years’
[10]. In Europe there are various, ‘Public realm’, measures against
smoking, such as speciﬁc excise taxes on tobacco [61] and the ban
on tobacco advertising in the entire European Union (EU) [61].
Currently, 17 EU countries have smoke free laws in place, such
as a ban on smoking in public spaces and in the workspace [62].
Additionally, the EU has developed multiple anti-smoking
campaigns [63].
Population-level impact
There is some conﬂicting evidence on the effectiveness of mass
media campaigns in reducing smoking uptake and prevalence
[64]. While the vast majority are shown to be effective [64, 65],
there is a need to be careful about the campaign message and
mode of delivery in order to be effective [64]. Policies which ban
smoking in public places and the workspace have been shown
to be effective in reducing tobacco consumption [66, 67]. How-
ever, according to The Lancet Commissions, speciﬁc excise
taxes are the most effective intervention against tobacco use
and related non-communicable diseases at population level
[68]. TheWHO estimated that doubling prices on tobacco by rais-
ing speciﬁc excise taxes would lead to an increase in tobacco tax
revenues of $100 billion [69], despite reducing tobacco consump-
tion by one third [61]. In contrast, reducing tobacco consumption
by a third through other measures would actually lead to an esti-
mated decrease in tobacco tax revenue of $100 billion [69]. To-
bacco-speciﬁc excise taxes are therefore highly cost effective.
Recently Bilano et al. [70] reported the global trends for to-
bacco use. From 2000 to 2010, tobacco use decreased in men in
all 31 European high-income countries, but in women tobacco
use decreased only in 27 of these countries [70]. Smoking cessa-
tion appears to improve kidney function, yet established protein-
uria seems to be irreversible [71, 72]. The increase in life
expectancy after smoking cessation in the general population
has been well documented [61].
Additional high-risk level measures
Several studies have documented that smoking in people with
CKD and people at risk for CKD is related to both progression of
CKD and cardiovascular mortality [13]. Hence smoking cessation
is recommended for people with CKD [1]. There are few studies
which investigate how often smoking cessation counselling is re-
commended by physicians. A study performed in hospitalized
CKD patients with heart failure found that smoking cessation
counselling is less often promoted as kidney function declines
[73]. Another study performed in patients at-risk for CVD, includ-
ing 923 CKD patients, found that in Canadian primary care about
50% of smokers received smoking cessation counselling [74].
Plenty of residual opportunity therefore remains to promote
smoking cessation in clinical contexts.
High-risk level impact
To our knowledge no studies are available on the effectiveness of
smoking cessation strategies in people with CKD [13]. Although
only few studies have investigated the effect of smoking cessa-
tion on renal function in people with CKD, all studies found a
positive effect [13].
Non-communicable diseases as risk factors
Diabetes
CKD screening in diabetic patients
Screening for kidney disease in people with diabetes is now gen-
erally recommended [75]. Moreover, several studies have



























suggested that CKD screening is cost effective in this context [76,
77]. Nonetheless, adherence to CKD screening guidelines varies
markedly across countries and between physicians [78, 79].
Treatment of diabetes
Multiple studies have shown that the development and progres-
sion of albuminuria in diabetic subjects can be prevented
through strict glycaemic control and the use of angiotensin con-
verting enzyme inhibitors (ACEi) [80–82]. Accordingly, the use of
glycaemic control medication and ACEi in diabetic subjects has
increased over the years [83, 84]. Golan et al. [77] have proposed
that treating all middle-aged type 2 diabetics with ACEi is the
most cost-effective strategy to slow progression to end-stage
renal disease (ESRD).
The impact of this improved treatment of diabetes on CKD
and its complications is unclear. Some studies have described
the trends in diabetic kidney disease prevalence, yet these are in-
ﬂuenced by both incidence and survival [83, 84]. There are some
reports on the change of renal replacement therapy (RRT) inci-
dence for ESRD due to diabetes. From 1996 to 2006 the incidence
of RRT for ESRD in diabetics decreased in the USA [85]. This is in
line with results from Europe, in which the incidence of RRT for
ESRD due to type 1 and 2 diabetes in the general population de-
creased between 1998 and 2011 [86]. Although this decline may
be due to slower progression of CKD caused by improved treat-
ments and earlier detection, it may also be partly explained by
a change in renal replacement initiation practices.
Hypertension
CKD screening in hypertensive patients
Almost all guidelines recommend screening for CKD in hyperten-
sive subjects [87, 88]. Boulware et al. [89] have shown that screen-
ing in hypertensive subjects is cost-effective irrespective of age.
Treatment of hypertension
Although hypertension increases the risk of developing CKD,
there is no clear evidence that blood pressure reduction lowers
that risk [90, 91]. Importantly, hypertension is among the biggest
single disease risk factors for global disease burden [3] and there-
fore hypertension treatment should be a high priority at the
population level even if evidence of its impact on CKD incidence
is limited. In CKD patients, treatment of hypertension is recom-
mended to reduce CKDprogression and lower cardiovascular dis-
ease risk [1]. Medication adherence to antihypertensive agents
within CKD patients has been estimated to be around 67% [92].
Using data from the Health Survey for England, Aitken et al.
[84] observed an increase in the use of antihypertensive drugs
in hypertensive subjects in England between 2003 and 2008. In
this same period, the systolic and diastolic blood pressure de-
creased in the hypertensive populationwhile theCKDprevalence
within the hypertensive population stayed approximately the
same [84].
In CKD patients there is evidence that more could be done to
improve blood pressure control. Several studies have identiﬁed
that recommended blood pressure targets are only achieved in
<50% of patients [56, 93]. A study in CKD patients in primary
care found that older age, greateralbuminuria levels and diabetes
were all associated with poorer blood pressure control [93].
Conclusion
In this narrative review we have discussed ﬁve important CKD
risk factors that are targeted by the WHO Action Plan for the
Prevention and Control of NCDs: physical inactivity, high dietary
salt intake, smoking, diabetes and hypertension. Considering the
framework proposed by Ogilvie et al.wehave describedmeasures
involving various stakeholders, such as policy makers, health
practitioners and the food industry. Thus highlighting the im-
portance of seeing the ‘big picture’ when reviewing the transla-
tion of research in the context of public health.
Lifestyle factors
At the population level, all three lifestyle risk factors were trans-
lated to implemented measures, varying from campaigns pro-
moting physical activity and reducing dietary salt intake to
speciﬁc excise taxes on tobacco. The implemented lifestyle mea-
sures appeared to have a positive impact at the population level,
as physical inactivity, dietary salt intake and smokingwere all re-
duced after implementation of population-wide measures. The
population health impact was mostly shown in studies focusing
on cardiovascular outcomes and mortality reductions. Only few
studies have described the impact of lifestyle improvements on
kidney outcomes, which were limited to proteinuria and kidney
function.
At the ‘high-risk’ level, the discussed lifestyle studies focused
on the individual impact of interventions.Wewere unable to ﬁnd
studies investigating to what extent successful measures were
implemented in CKD health practice.
NCDs as risk factors for CKD
The treatment of both diabetes andhypertension appears to have
improved with increased prescription rates for glycaemic control
medication, ACEi and antihypertensive medication. However,
studies on blood pressure control suggest that blood pressure
control remains poor in CKD patients, especially in diabetic
CKD patients. As with other conditions, the uncontrolled roll
out of treatment improvements to the high-risk patients makes
the impact on development of CKD and CKD complications difﬁ-
cult to establish.
Limitations
The importance of risk factors may vary per region [7] and we
have only described studies performed in Western developed
countries. As CKD and its inﬂuence on public health are inﬂu-
enced by many factors, we could not provide a comprehensive
overview of all relevant factors. We recognize, for example, that
other factors, such as obesity, have an important impact on kid-
ney function (either directly or indirectly via inﬂuencing blood
pressure or other mediators) [2]. We chose to focus on a selected
group of major determinants of global morbidity and mortality,
and described ﬁve factors speciﬁcally highlighted by the WHO
Action Plan for the Prevention and Control of NCDs. However,
even within this selected group, we did not perform a systematic
search and consequently we may have failed to include relevant
studies. Nonetheless we believe that the topics discussed de-
scribe important exemplars of translational research and
achievements with regard to CKD prevention and public health.
Recommendations for future research
There is a need for population-level studies focusing on the im-
pact of lifestyle measures on hard renal outcomes such as start
of RRT. Moreover, longitudinal studies are needed to prove caus-
ation between implementedmeasures and associated outcomes.



























With regard to high-risk levelmeasures, studies are needed to
investigate the implementation of recommended measures in
CKD health practice. Importantly, to fully assess the impact of
implemented measures on the CKD population at large, one
needs either registries or studies that repeatedly collect data on
both measures and associated outcomes in CKD populations.
Of note, we have discussed ﬁve important risk factors for CKD,
but there aremultiple other important factors andmeasures rele-
vant to the prevention of CKD and its complications, such as
acute kidney injury [94], alcohol use [95] and (dietary) interven-
tions for obesity [7]. Since in low- and middle-income countries
the burden of CKD and related non-communicable diseases is in-
creasing rapidly [3], there is an urgent need for understanding the
most effective translational interventions in these countries.
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